Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Inventory (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Inventory for 7 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory fell 14.79% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, down 14.79%, and an annual FY2025 reading of $4.0 million, down 14.79% over the prior year.
  • Inventory was $4.0 million for Q4 2025 at Karyopharm Therapeutics, up from $4.0 million in the prior quarter.
  • Across five years, Inventory topped out at $5.0 million in Q2 2025 and bottomed at $2.8 million in Q1 2024.
  • Average Inventory over 5 years is $3.9 million, with a median of $3.9 million recorded in 2021.
  • The sharpest move saw Inventory soared 221.03% in 2021, then fell 27.96% in 2023.
  • Year by year, Inventory stood at $4.1 million in 2021, then rose by 2.87% to $4.2 million in 2022, then decreased by 27.96% to $3.0 million in 2023, then skyrocketed by 55.73% to $4.7 million in 2024, then fell by 14.79% to $4.0 million in 2025.
  • Business Quant data shows Inventory for KPTI at $4.0 million in Q4 2025, $4.0 million in Q3 2025, and $5.0 million in Q2 2025.